PeopleBio피플바이오
304840 · KOSDAQ · ₩304840 · 피플바이오
- Market cap
- ₩14B
- Enterprise value
- ₩89B
- P/E
- —
- P/B
- 0.5×
- Dividend yield
- 0.0%
- ROE
- −53.3%
- Net margin
- −421.0%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−75.0% from the high
₩561Today: ₩561 – ₩561₩2,245
Returns
- 1W0.0%
- 1M0.0%
- 3M−21.5%
- 6M−58.4%
- YTD−47.5%
- 1Y−62.8%
- Volume today
- —
- Traded today
- —
- Listed shares
- 24,320,660
- EPS (12 months)
- −₩632
- Earnings yield −112.6%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 43 of 100 (50 is a normal day for this stock).
- MomentumFlat0% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
PeopleBio stock overview
PeopleBio (피플바이오, KRX: 304840) is listed on KOSDAQ, in the Biotech & Pharma sector. The company develops blood-based diagnostic tests for Alzheimer's disease, centered on its proprietary SI-MDS technology that measures oligomeric beta-amyloid. Its shares closed at ₩561 on Oct 27, 2026, unchanged on the day, giving it a market value of ₩14B.
Key facts
- Market cap
- ₩14B
- Sector
- Biotech & Pharma
- Latest price change
- 0.00%
- As of
- Oct 27, 2026
- Main business
- The company develops blood-based diagnostic tests for Alzheimer's disease, centered on its proprietary SI-MDS technology that measures oligomeric beta-amyloid.
Quick answers about PeopleBio
- What does PeopleBio do?
- The company develops blood-based diagnostic tests for Alzheimer's disease, centered on its proprietary SI-MDS technology that measures oligomeric beta-amyloid. Its main product, AlzOn, is an in-vitro diagnostic device sold domestically in Korea and exported through partners, including to the Philippines, and it has obtained CE marking for the European market. The company also says the underlying platform can be extended to other protein-misfolding diseases, and it conducts joint research with domestic and overseas institutions and hospitals.
- What is the market cap of PeopleBio?
- The market capitalisation of PeopleBio was ₩14B at the close on Oct 27, 2026.
- Who are the largest shareholders of PeopleBio?
- According to the latest official filings, the largest reported holders are Human Data (57.69%, as of Oct 8, 2026); Samho SH Investment Advisory (57.69%, as of Oct 8, 2026); Kang Sung-min (25.02%, as of Nov 12, 2024).
- When is the next earnings report from PeopleBio?
- Korean companies rarely announce results dates in advance. Based on when PeopleBio filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
The company develops blood-based diagnostic tests for Alzheimer's disease, centered on its proprietary SI-MDS technology that measures oligomeric beta-amyloid. Its main product, AlzOn, is an in-vitro diagnostic device sold domestically in Korea and exported through partners, including to the Philippines, and it has obtained CE marking for the European market. The company also says the underlying platform can be extended to other protein-misfolding diseases, and it conducts joint research with domestic and overseas institutions and hospitals.
Written by AI from the company's latest annual report.
- Korean name
- 피플바이오
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 강성민, 전용범
- Founded
- Sep 2002
- Listed
- Oct 2020
- Listed shares
- 24,320,660
- Fiscal year ends
- Month 12
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- [Amended] Decision on Share ConsolidationOct 21, 2026
- 5%+ holding reportOct 8, 2026
- 5%+ holding reportOct 8, 2026
- Decision to Provide Collateral for Third PartySep 28, 2026
- [Amended] Decision on Share ConsolidationSep 22, 2026
Titles in Korean until English translations are added.
Also known as: PeopleBio / 피플바이오 / 304840 / KRX:304840
Source: KRX statistical information